This is a repository copy of *Mifamurtide for the treatment of nonmetastatic osteosarcoma.*

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/98189/

Version: Submitted Version

**Article:**

https://doi.org/10.1517/14656566.2011.543129

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Please download and read the instructions before proceeding to the peer review

**Mifamurtide for the treatment of non-metastatic osteosarcoma**

<table>
<thead>
<tr>
<th>Journal:</th>
<th><em>Expert Opinion On Pharmacotherapy</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID:</td>
<td>EOOP-2010-0284.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Drug Evaluation</td>
</tr>
<tr>
<td>Keywords:</td>
<td>osteosarcoma, liposomal muramyl tripeptide phosphatidylethanolamine, mifamurtide, macrophage, chemotherapy, innate immunity</td>
</tr>
</tbody>
</table>
Mifamurtide for the treatment of non-metastatic osteosarcoma

Kosei ANDO1,*, Kanji MORI1, Nedège CORRADINI2,3,4, Françoise REDINI2,3 and Dominique HEYMANN2,3,5,*

1 Department of Orthopaedic Surgery, Shiga University of Medical Science, Otsu, Shiga, 520-2192, Japan

2 INSERM, UMR 957, Nantes, F-44035 France

3 Université de Nantes, Nantes atlantique universités, Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives

4 CHU de Nantes, Service d’Oncologie Pédiatrique, France

5 CHU de Nantes, Pôle de Biologie, France

*Address correspondence and reprint requests

Dr Kosei ANDO: Tel, +81-77-548-2252; Fax, +81-77-548-2254; email, ando-ko@mx.scn.tv

Pr Dominique HEYMANN : Tel, + 33 (0) 240 412 845 ; fax, +33 (0) 240 412 860 ; email, dominique.heymann@univ-nantes.fr

URL: http://mc.manuscriptcentral.com/eoop Email: Elizabeth.Knowles@informa.com
Abstract

Importance of the field

Osteosarcoma belongs to the orphan diseases but is the most common primary malignant tumor of bone. Currently, the standard treatment for osteosarcoma requires both macroscopic surgical wide resection and postoperative multi-drug chemotherapy in neo-adjuvant and adjuvant settings. However, the 5-year event-free survival remains at a plateau of 60-70% of patients with non-metastatic osteosarcoma for over 30 years.

Areas covered in this review

Mifamurtide [liposomal muramyl tripeptide phosphatidylethanolamine (L-MTP-PE)] is a new agent. L-MTP-PE is a nonspecific immunomodulator, which is a synthetic analog of a component of bacterial cell walls. L-MTP-PE activates macrophages and monocytes as a potent activator of immune response. The addition of L-MTP-PE to standard chemotherapy improves the overall survival from 70% to 78% and results in a one-third reduction in the risk of death from osteosarcoma.

What the reader will gain

Recently, L-MTP-PE has been approved in Europe for the treatment of non-metastatic osteosarcoma with chemotherapy. According to preliminary clinical report, L-MTP-PE is well-tolerated and has little severe side effects.
Take home message

L-MTP-PE in combination with traditional treatment is expected to go mainstream and to be beneficial for patients with osteosarcoma.

Key words osteosarcoma, liposomal muramyl tripeptide phosphatidylethanolamine, macrophage, chemotherapy, innate immunity
1. Introduction

Osteosarcoma is the most common primary malignant bone tumor. It usually arises in the metaphyses of long bone in children and adolescents [1, 2]. Approximately 1000 new patients are seen per year in North America and a similar number in Europe [3]. The standard treatment of the primary osteosarcoma consists of microscopically complete surgical resection and multi-agent chemotherapy in neo-adjuvant and adjuvant settings. Surgical techniques for osteosarcoma have improved and built up from amputations to limb-salvage surgery during the last decades [4]. However, it did not contribute to the improvement of both EFS and overall survival.

On the other hand, the value of chemotherapy for treatment of osteosarcoma is well established [5, 6]. There are currently four chemotherapeutic agents, which consist of doxorubicin, cisplatin, high-dose methotrexate with leucovorin rescue, and ifosfamide [7-11]. Vigorous chemotherapy treatment with these agents has significantly improved survival of the osteosarcoma patients over the past several decades [12]. It has been reported that EFS of osteosarcoma patients at 3-5 years has reached 60-70% in the non-metastatic condition. However, in the metastatic relapse or recurrent conditions, EFS of osteosarcoma patients at 3-5 years remained at 10-30% since early 1980s [4, 12-14]. None of the various chemotherapy agents and regimens has demonstrated any
significant superiority yet [15]. No new anti-osteosarcoma agents have been developed in the intervening years [16]. Recently, Children’s Oncology Group carried out long-term follow-up of the key trial of chemotherapy with or without mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine [L-MTP-PE]). This group demonstrated that addition of L-MTP-PE to chemotherapy significantly improved overall survival at 6 years from 70% with chemotherapy alone to 78% with chemotherapy and L-MTP-PE (p = 0.03) [17]. These data demonstrate that L-MTP-PE may have a potential role in the improvement of survival of the osteosarcoma patients remained on a plateau for over two decades [16, 18-20]. The proprietary product name of mifamurtide is Mepact® (Takeda). L-MTP-PE, a nonspecific immunomodulator, is a synthetic analog of a component of bacterial cell walls [21]. L-MTP-PE activates macrophages and monocytes as a potent activator of immune response [22, 23].

In this review, we will summarize the most recent findings about L-MTP-PE and its therapeutic application for non-metastatic osteosarcoma.

2. Pharmacology

MTP-PE is a stimulator of innate immunity and a synthetic molecule derived from muramyl dipeptide (MDP). MTP-PE results from the covalent addition of alanin and
dipalmitoyl phosphatidyl ethanolamine to MDP (Figure 1), which is a peptidoglycan found in Gram-positive and Gram-negative bacterial cell walls [21].

**In vitro and in vivo** monocytes/macrophages activation by MTP-PE is related to the upregulation of tumoricidal activity and secretion of pro-inflammatory cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, IL-8, nitric oxide (NO), prostaglandin E2 (PGE2), and PGD2 [24-29]. NO, PGE2, and PGD2 are synthesized and released by murine Kupffer cells (liver macrophages) after *in vitro* MTP-PE exposure [30]. Moreover, L-MTP-PE induces the expression of adhesion molecules including lymphocyte function-associated antigen (LFA)-1, intracellular adhesion molecule (ICAM)-1, and human leukocyte antigen (HLA)-DR. These molecules could be closely related to interaction with tumor cells [21, 31].

MTP-PE is superior to MDP in the activation of human monocytes [22]. The lipophilic MTP-PE could be efficiently incorporated in the lipid bilayer of liposomal structures and distributed primarily in the liver, spleen, and lungs after intravenous MTP-PE administration [22, 23, 32]. Thus, the intravenous MTP-PE encapsulated in liposomes has been developed to target delivery of the drug selectively to monocytes and macrophages, such as those in liver, spleen, and lungs [13, 16, 21]. **The lipid composition of mifamurtide also facilitates macrophage signaling via phosphatidyl**
serine recognition by macrophages [33]. The particle nature of liposomes converts the parent drug into ‘‘pro-drug’’. Liposomes are concentric multi-lamellar vesicles with the lipid bilayers resembling an onion of particle size approximately 2-3 μm. Formulation of MTP-PE into these phospholipid vesicles enhances the activation of macrophages/monocytes tumoricidal properties and extends its existence in the lungs [22, 32]. In fact, an advantage of MTP-PE over MDP in the activation of human monocytes was demonstrated [22]. This advantage was ascribed to the benefit of the lipophilic properties of MTP-PE described earlier. In addition, the liposomal formulation (L-MTP-PE) has improved the safety profile of several drugs by modifying parent drug or solubilization agent toxicity [34]. Due to rapid mononuclear phagocytosis of the liposome transporter, L-MTP-PE has very rapid clearance from the blood only approximately 0.5% of L-MTP-PE remains in the plasma at the 5-min time point compared with 93% when administrated as the free form [35]. In humans, there is no evidence of accumulation of either liposomes or free MTP-PE after L-MTP-PE 4-mg treatment twice a week for 9 week [36]. The half-life of free MTP-PE can be estimated as 3-6 h from dog and rat studies. Additionally, no accumulation of phospholipids after repeated administration has been confirmed [32]. Due to such the rapid clearance, L-MTP-PE shows ten times lesser adverse event level than free MTP-PE in rabbits and
dogs [21].

MTP-PE can bind to Toll-like receptor (TLR) 4 and activate extracellular-signal regulated kinase 1/2 (ERK 1/2), nuclear factor-kappa B (NF-κB) and adaptor protein (AP)-1 [29, 37]. However, the other receptor for MTP-PE may be intracellular [22]. Recently, MTP-PE has been reported as a specific ligand of nucleotide-binding oligomerization domain (Nod) 2 receptor. Nod2, an intracellular MDP sensor, is strongly expressed in monocytes, granulocytes, myeloid dendritic cells, and macrophages [38]. It induces NF-κB and influences the innate immune response [39]. L-MTP-PE is selectively phagocytosed by monocytes and macrophages after intravenous administration [40]. The phagocytic cells gradually degrade the liposomal vesicles. Then, MTP-PE is released into the cytosol and is degraded to MDP where it interacts with Nod2 and activates the cells [22, 41]. Thus, monocytes/macrophages activation by L-MTP-PE is considered to be mediated via Nod2 [16, 21] (Figure 2). In sum, preclinical studies showed that L-MTP-PE, in comparison with free MTP-PE, was more effective in terms of activating monocytes [22], was longer held in target organs [32], and was 10-fold less toxic [42].

Monocytes activated by L-MTP-PE had no effect on non-tumorigenic cells [24, 26, 43] and even under conditions of co-cultivation with tumorigenic cells [24, 43].
Furthermore, peripheral blood monocytes from patients with cancer could be activated to similar levels of tumoricidal activity as monocytes from healthy volunteers [26, 39, 43, 44]. L-MTP-PE interacts with interferon (IFN)-γ to up-regulate tumoricidal activity and to induce secretion of cytokines such as TNF-α and IL-1β [21, 45-50]. The mechanism of this potentiation remains to be elucidated, but a 2-fold increase in liposome phagocytosis was observed after treatment of human monocytes with IFN-γ [50].

Activation of monocytes-mediated tumoricidal activity was investigated following in vivo treatment with L-MTP-PE in phase I and II clinical trials [36, 51, 52]. In the phase I study, 28 patients with metastatic cancer received increasing doses (1h intravenous administration) of L-MTP-PE (0.05-12.0 mg/m²) twice a week [36, 51]. Peripheral blood monocytes were harvested and examined ex vivo for cytotoxic activity against human A375 melanoma cells before L-MTP-PE therapy and at various time points during the 9-week treatment period. Activation of monocytes-mediated cytotoxic activity was seen in 24 (86%) of the 28 patients at some time points during the treatment period [51]. Monocytes-mediated tumoricidal activity remained for up to 96 hours after initial mifamurtide infusion [36]. In the phase II study, 16 patients with relapsed osteosarcoma received a 1h intravenous infusion of L-MTP-PE (2 mg/m²) twice a week for 12 weeks [52]. These patients had histologically confirmed osteosarcoma and
pulmonary metastases that had developed during adjuvant chemotherapy or that were present at diagnosis and had persisted despite chemotherapy. The patients were pre-treated with surgical resection of visible and palpable lung metastases before participating in the study. Peripheral blood monocytes were harvested and examined *ex vivo* for cytotoxic activity against human A375 melanoma cells before L-MTP-PE therapy and during the 4-week treatment period. Monocytes-mediated tumoricidal activity was significantly increased in 80% of the patients evaluated. The peak cytotoxic activity was observed at 24 (n = 3), 72 (n = 4), and 96 (n = 1) hours post-infusion [52]. Similarly, monocytes and macrophages from non-human species demonstrated increased tumoricidal activity after *in vitro* [25, 28] and *in vivo* [28, 46, 53-55] treatment with L-MTP-PE or MTP-PE.

Although various chemotherapeutic agents and regimens have been examined for osteosarcoma, none of them demonstrates any clear superiority [15, 56]. Since L-MTP-PE was intended to be used *in combination with both adjuvant chemotherapy and surgery* in the treatment of osteosarcoma, some researchers reported the effects of cytotoxic agents on the monocytes-mediated tumoricidal activity of L-MTP-PE [39, 57, 58]. These results showed that most chemotherapeutic drugs including the treatment of osteosarcoma (*i.e.*, doxorubicin, cisplatin, high-dose methotrexate with leucovorin rescue,
and ifosfamide) did not influence on macrophage activation by L-MTP-PE [39, 57, 58]. For example, doxorubicin [39, 57], cisplatin [39], methotrexate [39], or cyclophosphamide [39] administration to patients with osteosarcoma did not interfere with the ability of L-MTP-PE to enhance the monocytes-mediated tumoricidal activity from these patients in vitro. Furthermore, combination chemotherapy of doxorubicin and cyclophosphamide strongly suppressed monocytes-mediated tumoricidal activity by L-MTP-PE [39]. Similarly, simultaneous administration of ifosfamide and L-MTP-PE did not interfere with the ability of L-MTP-PE to activate an in vivo immune response according to the results of a phase IIb clinical study in patients with relapsed osteosarcoma (n = 9) [58]. The trial participants had histologically confirmed osteosarcoma and pulmonary metastases that had developed during adjuvant chemotherapy or that were present at diagnosis and had persisted despite chemotherapy. They were treated neoadjuvantly and/or adjuvantly with a combination of ifosfamide (up to 8 cycles in total; each cycle consisted of 1.8 g/m² for 5 days every 21 days) and L-MTP-PE (2 mg/m² twice a week for 12 weeks and then once a week for 12 weeks). Up-regulations of serum TNF-α, IL-6, and IL-8 in patients treated with the combination therapy was not different from those in patients treated with L-MTP-PE alone [52]. In addition, monocytes-mediated tumoricidal activity was elevated at 24 and 72 hours after
the initial of combination therapy, similar to the following L-MTP-PE alone [51]. In particular, combination treatment of ifosfamide and L-MTP-PE did not increase the toxicity of ifosfamide [58]. L-MTP-PE did not decrease the tumoricidal activity of ifosfamide or doxorubicin in three synergistic murine tumor models [59]. Furthermore, the suggested course of L-MTP-PE therapy did not worsen the identified renal (i.e., cisplatin, ifosfamide) or hepatic (i.e., methotrexate, ifosfamide) toxicities of the concurrently administered chemotherapies in phase III study in patients with osteosarcoma [60].

3. Clinical therapeutic efficacy

A phase III randomized prospective trial was conducted by the Children’s Cancer and Pediatric Oncology Groups (now collectively known as the Children’s Oncology Group) from 1993 to 1997 [12]. This central randomized trial in osteosarcoma was known as the Intergroup Study 0133 (INT study 0133). A total of 662 eligible patients aged ≤ 30 years with non-metastatic resectable osteosarcoma were employed in this study [17]. This study was designed to assess whether the addition of L-MTP-PE and/or ifosfamide to a standard chemotherapeutic regimen composed of three agents (i.e., doxorubicin, cisplatin and high-dose methotrexate with leucovorin rescue) would
increase both EFS and overall survival in newly diagnosed patients with high-grade osteosarcoma. No significant improvement in EFS and overall survival was observed by the addition of ifosfamide in the dose and schedule used in this study \( (p = 0.934 \text{ and } 0.992 \text{ respectively}) \). However, significant improvement in EFS and overall survival were observed in patients randomized to receive L-MTP-PE \( (p = 0.030 \text{ and } 0.039 \text{ respectively}) \). These findings correspond to a 25% reduction in the risk of recurrence and a 30% reduction in the risk of death \[21, 61\]. Most notably, the 6-year overall survival improved from 70% without L-MTP-PE to 78% with it \[17\].

In the INT study 0133, all patients were intended to receive a similar backbone treatment called MAP (\textit{i.e.}, high-dose methotrexate with leucovorin rescue, doxorubicin/adriamycin, and cisplatin) with identical cumulative doses of high-dose methotrexate (12 times at doses of 12 g/m\(^2\)), doxorubicin (6 times at doses of 75 mg/m\(^2\)), and cisplatin (4 times at doses of 120 mg/m\(^2\)). The randomized prospective study was conducted with a 2 \times 2 factorial design with 4 treatment groups: (1) MAP, (2) MAP + L-MTP-PE, (3) MAP + ifosfamide, and (4) MAP + ifosfamide + L-MTP-PE. Ifosfamide was administered 5 times at a dose of 9 g/m\(^2\) per course. L-MTP-PE was administered at a dose of 2 mg/m\(^2\) \textbf{in the adjuvant setting}. L-MTP-PE was administered intravenously twice a week for 12 weeks starting at week 12, and then weekly for additional 24 weeks.
starting at week 24. The duration of treatment was 20 weeks for patients randomly assigned to ‘MAP’ group, 27 weeks for patients randomly assigned to ‘MAP + ifosfamide’ group, and 36 weeks for patients randomly assigned to ‘MAP + L-MTP-PE’ group and ‘MAP + ifosfamide + L-MTP-PE’ [12, 17]. The results of INT study 0133 were analyzed and published in 2005 and 2008 [12, 17]. In 2005, Meyers et al. [12] reported their initial analysis of EFS without overall survival. According to their findings, there was no significant evidence of L-MTP-PE on EFS [12]. Later, this initial report was cited as inappropriate analyses. In 2008, both overall survival and EFS were renewed as the result of subsequent analysis of this study with longer follow-up [17]. This re-analysis reported improved overall survival with the addition of L-MTP-PE from 70% to 78% 6-year overall survival ($p = 0.03$) [17]. By contrast, in the analysis of EFS, there was no sufficient evidence of the interaction ($p = 0.102$) [17]. This makes the interpretation of INT 0133 study very complicated [62, 63] because the effect of treatment on overall survival is expected to be mediated through EFS. There were no differences in the frequency of favorable tumor necrosis, which is strongly associated with EFS and determined by modified Huvos grading [64], among those treatment groups. Therefore, the authors concluded that ifosfamide and the other chemotherapy agents are equivalent in their ability to contribute to favorable tumor necrosis. Furthermore, another
study demonstrated that patients with metastatic osteosarcoma were given a good benefit by administration of a higher dose of ifosfamide (14 mg/m$^2$) [65, 66]. Thus, the most effective combination of ifosfamide with L-MTP-PE may be a dose question. At any rate, many additional questions including the best way to combine chemotherapy and L-MTP-PE still remain, but the INT study 0133 demonstrated the possible benefit associated with L-MTP-PE in the treatment of osteosarcoma.

4. Dosage and Side effects after premedication

In European Union, L-MTP-PE is indicated in patients with high-grade, resectable, non-metastatic osteosarcoma after the complete surgical wide resection aged between 2 and 30 years [60]. It is currently recommended that L-MTP-PE is intravenously-administered over 1 hour twice weekly for an initial 12 weeks, followed by once weekly for an additional 24 weeks (total 48 infusions in 36 weeks) [17]. Since all patients recently receiving L-MTP-PE on a compassionate basis have had evidence of biologic activity at 2 mg/m$^2$, premedication and use of the fixed 2 mg/m$^2$ dose is suggested. The preparation and infusion of L-MTP-PE has recently been validated in numerous processes, and these are reproducible and easily performed in the outpatient setting.
L-MTP-PE therapy was generally well tolerated [36, 67]. The most commonly reported side effects are listed in Figure 3. Most of those side effects were severe [60]. In the phase I and II studies, there was no evidence of dose-dependent [68], cumulative [36], and organ-related [68] toxicity in association with L-MTP-PE. Furthermore, the majority of patients experienced side effects with the initial administration of the agent [36, 69]. The major side effects of L-MTP-PE administration are fever and chills. They are typically transient and generally respond to the treatment [60]. The possibility of anti-inflammatory drugs relieving these adverse effects has been investigated. Premedication such as ibuprofen [70] can help prevent the severity of fever and chills. However, high-dose ibuprofen (> 40 μg/ml) with L-MTP-PE down-regulates the antitumor effect and the production of IL-1 and TNF-α in monocytes [70]. The antitumor effect of L-MTP-PE was lost in a murine fibrosarcoma model using diclofenac [71]. These findings suggest that anti-inflammatory agents such as cyclooxygenase inhibitors can down-regulate the antitumor effect of L-MTP-PE. For ibuprofen-resistant cases, acetaminophen and/or meperidine are recommended as alternative agents [13]. Specifically, ibuprofen 200 or 400 mg is given as a premedication. If fever and/or chills occur, acetaminophen (15 mg/kg; up to 1000mg) may be given. If needed more, both acetaminophen and ibuprofen may be additionally utilized to improve the symptoms [17, 60].
5. Expert Opinion

The orphan disease limits the number of patients available to study. Osteosarcoma is an orphan disease with fewer than 1500-2000 new cases per year diagnosed in the USA similar to Europe. Indeed, except L-MTP-PE, only IFN-α study are undergoing as international cooperative trial for osteosarcoma adjuvant chemotherapy. The efficacy of IFN-α, which is initiated after postoperative chemotherapy, is investigated by EURAMOS 1 [40]. Unfortunately, this trial is still under the recruitment phase [19]. Therefore, L-MTP-PE, the first new agent approval for the treatment of osteosarcoma in over 20 years, is strongly expected to become ‘routine’ for both oncologists and patients with osteosarcoma. Information about potential benefit regarding mifamurtide use in the neoadjuvant setting (i.e. before surgery) and/or utility of L-MTP-PE in metastatic in relapsed and metastatic osteosarcoma will require analysis of expanded access and/or future clinical trials of L-MTP-PE in high burden and low burden situations.
Figure legends

Figure 1: The molecular structure of liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE).

Figure 2: Nod2 is an intracellular MDP sensor. Monocytes/macrophages activation by L-MTP-PE is mediated via Nod2. L-MTP-PE is selectively phagocytosed by monocytes and macrophages after intravenous administration. L-MTP-PE is released into the cytosol and degraded to MDP. Nod2 binding to MDP activates NF-κB and influences the innate immune response [41]. Abbreviations: Nod2; nucleotide-binding oligomerization domain 2, MDP; muramyl dipeptide, L-MTP-PE; liposomal muramyl tripeptide phosphatidyl ethanolamine, NF-κB; nuclear factor-kappa B.

Figure 3: Tolerability of mifamurtide. Major side effects in 248 patients with advanced cancer including 51 patients with osteosarcoma [36, 59, 66-68].

References


17. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's


25. Fogler WE, Fidler IJ. Nonselective destruction of murine neoplastic cells by


32. Fogler WE, Wade R, Brundish DE, et al. Distribution and fate of free and


55. Smith BW, Kurzman ID, Schultz KT, et al. Muramyl peptides augment the in vitro
and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells. Cancer Biother 1993;8:137-44.


60. MEPACT 4 mg powder for suspension for infusion: summary of product characteristics. Paris: IDM. In; 2010.


70. Fujimaki W, Griffin JR, Kleinerman ES. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune


## Drug Summary Box

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Mifamurtide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase</td>
<td>Launched</td>
</tr>
<tr>
<td>Launched indication</td>
<td>osteosarcoma</td>
</tr>
<tr>
<td>Pharmacology description</td>
<td>Macrophage stimulant</td>
</tr>
<tr>
<td>Route of administration</td>
<td>Parenteral, intravenous</td>
</tr>
<tr>
<td>Chemical structure</td>
<td>C₅₉H₁₀₉N₆O₁₉P</td>
</tr>
<tr>
<td>Pivotal trial(s)</td>
<td>Phase III</td>
</tr>
</tbody>
</table>

Pharmaprojects - copyright to Citeline Drug Intelligence (an Informa business). Readers are referred to Pipeline (http://informa-pipeline.citeline.com) and Citeline (http://informa.citeline.com).
Declaration of interest:

The authors state no conflict of interest and have received no payment in preparation of this manuscript